Omega Fund Management, LLC

Q2 2025 13F Holdings

  • Location
    boston, MA
  • Num holdings

    13

  • Value ($000)

    $154,437

  • Date Filed
    08/14/2025
  • Form type
    13F-HR
  • CIK
    0001637359
  • All SEC filings
  • Note
    Holdings aggregated across “other managers” listed in original SEC filing, see here for detailed holdings broken out by other managers
Compare Q2 2025 to
Select Quarter
Issuer Name
Class
CUSIP
VALUE
%
Shares
Principal
Option Type
---

Beta Bionics Inc.

COMMON STOCK
08659B102
$28.95M
19 %

1,988,287

---

Kestra Med Technologies Ltd.

COMMON STOCK
G52441105
$27.29M
18 %

1,645,893

---

Upstream Bio Inc.

COMMON STOCK
91678A107
$22.36M
15 %

2,036,293

NUVB
NUVB

Nuvation Bio

COMMON STOCK CLASS A
67080N101
$21.53M
14 %

11,042,728

---

Bicara Therapeutics Inc.

COMMON STOCK
055477103
$20.48M
13 %

2,204,650

REPL
REPL

Replimune Group

COMMON STOCK
76029N106
$18.35M
12 %

1,975,203

LXEO
LXEO

Lexeo Therapeutics

COMMON STOCK
52886X107
$4.76M
3 %

1,184,636

IKNA
IKNA

Ikena Oncology

COMMON STOCK
45175G108
$3.01M
2 %

2,249,123

SANA
SANA

Sana Biotechnology, Inc.

COMMON STOCK
799566104
$2.30M
2 %

843,750

ALMS
ALMS

Alumis Inc.

COMMON STOCK
022307102
$1.96M
1 %

653,223

Rows Per Page
10
  • 10
  • 50
  • 100
1 - 10 of 13